Blog
RSS FeedPosted by Michael Wonder on 01 Oct 2018
NHS England agrees to fund Janssen’s Symtuza
1 October 2018 - NHS England has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen ...
Posted by Michael Wonder on 01 Oct 2018
PHARMAC must fund breakthrough treatment
1 October 2018 - Cystic Fibrosis NZ and Kalydeco for Kiwis have launched a joint campaign urging PHARMAC to fund ...
Posted by Michael Wonder on 01 Oct 2018
SA Government’s free Meningococcal B vaccination program starts
1 October 2018 - A vaccine could have saved 18-year-old Jack Klemich from the meningococcal B disease that suddenly took ...
Posted by Michael Wonder on 01 Oct 2018
PBS listing timelines for new checkpoint inhibitors
1 October 2018 - The PBAC examined their PBS listing timelines at its recent special meeting. ...
Posted by Michael Wonder on 01 Oct 2018
Age-related macular degeneration: treatment at what cost?
29 September 2018 - An estimated 8·4 million people worldwide have moderate to severe vision loss caused by age-related macular degeneration. ...
Posted by Michael Wonder on 30 Sep 2018
Schedule of Pharmaceutical Benefits - 1 October 2018 update
1 October 2018 - The October 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 29 Sep 2018
New Zealand Pharmaceutical Schedule - 1 October 2018 update
1 October 2018 - The October 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Sep 2018
Ovarian cancer treatment to be made available to more women
28 September 2018 - The number of women with ovarian cancer now eligible for a powerful targeted treatment will dramatically ...
Posted by Michael Wonder on 28 Sep 2018
Revised PBS restrictions for ezetimibe & ezetimibe-statin effective 1 October 2018
28 September 2018 - As a result of the post-market review of ezetimibe, revised PBS restrictions for ezetimibe and ezetimibe-statin products ...
Posted by Michael Wonder on 28 Sep 2018
Recommendations made by the PBAC – August 2018
28 September 2018 - The recommendations from the August 2018 PBAC meeting are now available. ...
Posted by Michael Wonder on 28 Sep 2018
Publication of outcome from August 2018 PBAC special meeting
28 September 2018 - The brief outcome from the August 2018 special meeting regarding PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options ...
Posted by Michael Wonder on 28 Sep 2018
Decision to fund sapropterin
28 September 2018 - PHARMAC is pleased to announce a decision to list sapropterin (Kuvan), a treatment for the rare ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 27 Sep 2018
Differentiation of health-related quality of life outcomes between five disease areas: results from an international survey of patients
25 September 2018 - Health-related quality of life data generated by generic, preference-based instruments are highly demanded in health policy decision ...
Posted by Michael Wonder on 27 Sep 2018
Draft NICE decision rejects Respreeza for incurable, genetic disorder
27 September 2018 - NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in ...